CMS Corrects Error for IVL Procedures in ASC Setting – Retroactive TPT Payment Eligible for 2022
Welcome to The Catalyst
Change isn't quick. Unless it's when you experience Intravascular Lithotripsy (IVL) for the first time. Stay apprised of our latest news and insights while discovering how a simple and intuitive tool can be The Catalyst to change the way you think about calcium modification.
CMS Corrects Error for IVL Procedures in ASC Setting – Retroactive TPT Payment Eligible for 2022
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2, Reimbursement
Für eine deutschsprachige Version klicken Sie HIER
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2, Reimbursement
Verbesserte Kostenerstattung für koronare IVL in Deutschland
For an English language version, click HERE
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2, Reimbursement
Just five years ago, we were a start-up, commencing the launch of our pioneering treatment for calcified cardiovascular disease. Today we are a public company with customers in over 60 countries and a robust pipeline of technologies in various stages of development. Backed by solid clinical results, our intravascular lithotripsy (IVL) system has been used to treat more than 120,000 patients worldwide and we have every reason to believe it will help millions.
Topics: IVL Technology, SWAV News
Topics: Coronary IVL, IVL Technology, Coronary Clinical Data, Shockwave C2, Coronary Conferences, Treating Different Ca++ Morphologies, Female vs. Male Outcomes
Topics: Coronary IVL, IVL Technology, Coronary Clinical Data, Shockwave C2, Coronary Conferences, Treating Different Ca++ Morphologies, Female vs. Male Outcomes
It was smooth sailing for Shockwave this summer! Thank you to everyone who made Q3 unforgettable; but before we get cozy for the holidays, let’s reflect on the events that made the quarter one to remember. This year’s TCT was particularly momentous, as we announced the first prospective, female-only study of coronary interventions, EMPOWER CAD. We also explored tips and tricks for IVL with guide extension catheter usage with Dr. Stephan Heo and debated different approaches to modifying nodular calcium with an expert panel. Read up on the latest Shockwave IVL peer-written publications and more in the Q3 PulsePoint Newsletter.
Topics: Coronary IVL, Peripheral IVL, IVL Technology, Coronary Clinical Data, Peripheral Conferences, Peripheral Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, Shockwave S4, PulsePoint Newsletter, Calcium Corner, Shockwave M5 & Shockwave M5+, Female vs. Male Outcomes, Empower CAD
Join us in Las Vegas for VIVA 2022 as we crack into late breaking data supporting IVL’s consistency in calcium modification in real-world PAD. The late breaker, presented by Dr. Ehrin Armstrong, features the final 1,373 patient cohort datafrom the Disrupt PAD III Observational Study. Following the data release, an esteemed panel will discuss IVL’s consistent outcomes from both real-world AND randomized studies. Don’t roll the dice with calcium modification and join us at VIVA2022!
Topics: Peripheral IVL, IVL Technology, Peripheral Conferences, Peripheral Clinical Data
Did you get a chance to watch the educational symposium on nodular calcium at TCT 2022? If you missed it, we’ve got you covered!
Topics: Coronary IVL, IVL Technology, Coronary Clinical Data, Shockwave C2, Coronary Conferences, Treating Different Ca++ Morphologies, Female vs. Male Outcomes
Despite often being more challenging to treat, female PCI patients are under-represented in published data, with no dedicated prospective studies performed on this population. To address this unmet need, Shockwave is launching EMPOWER CAD, the first prospective, female-only study of coronary interventions.
Topics: Coronary IVL, IVL Technology, Coronary Clinical Data, Shockwave C2, Coronary Conferences, Treating Different Ca++ Morphologies, Female vs. Male Outcomes
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
